[HTML][HTML] Molecular biomarkers with potential clinical application in testicular cancer

J Lobo, AM Acosta, GJ Netto - Modern Pathology, 2023 - Elsevier
Testicular germ cell tumors (TGCTs) and sex cord-stromal tumors (SCSTs) are the most
common testicular neoplasms. The morphological spectrum of such tumors is wide, with …

MiRNA biomarkers in cancers of the male reproductive system: are we approaching clinical application?

V Constâncio, NT Tavares, R Henrique… - …, 2023 - Wiley Online Library
Background Specific cancer types face specific clinical management challenges. Owing to
their stability, robustness and fast, easy and cost‐effective detection, microRNAs (miRNAs) …

Detection of recurrence through microRNA-371a-3p serum levels in a follow-up of stage I testicular germ cell tumors in the DRKS-00019223 study

G Belge, C Dumlupinar, T Nestler, M Klemke… - Clinical Cancer …, 2024 - AACR
Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered
by low sensitivity and specificity of current biomarkers for detecting relapses. This study …

Circulating microRNAs for detection of germ cell tumours: a narrative review

CD Fankhauser, MM Nuño, MJ Murray, L Frazier… - European Urology …, 2022 - Elsevier
Testicular germ cell tumours (GCTs) are the most common malignancy among young men.
Management of GCTs relies on the serum tumour markers α-fetoprotein, human chorionic …

MicroRNA-371a-3p—The Novel Serum Biomarker in Testicular Germ Cell Tumors

T Nestler, J Schoch, G Belge, KP Dieckmann - Cancers, 2023 - mdpi.com
Simple Summary This review describes that miR371 is much more sensitive and specific
than the classical serum biomarkers of testicular germ cell cancer. There is a huge potential …

Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database

J Lauritsen, N Sauvé, A Tryakin, DM Jiang… - British journal of …, 2023 - nature.com
Background Active surveillance after orchiectomy is the preferred management in clinical
stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate. Patients …

[HTML][HTML] The value of tumour markers in the detection of relapse—lessons learned from the Swiss Austrian German Testicular Cancer Cohort Study

S Fischer, C Rothermundt, O Stalder, A Terbuch… - European urology open …, 2023 - Elsevier
The tumour markers alpha-fetoprotein (AFP), beta human chorionic gonadotropin (βHCG),
and lactate dehydrogenase (LDH) have established roles in the management and follow-up …

A stroll through the present and future of testicular germ cell tumour biomarkers

NT Tavares, R Henrique, A Bagrodia… - Expert Review of …, 2023 - Taylor & Francis
Introduction Testicular germ cell tumors (TGCT) are the most commonly diagnosed cancers
among young men. Although these tumors usually have a good prognosis and are highly …

MicroRNAs for detecting occult genitourinary cancer

NT Tavares, J Lobo, A Bagrodia - Current Opinion in Urology, 2024 - journals.lww.com
MicroRNAs for detecting occult genitourinary cancer : Current Opinion in Urology MicroRNAs for
detecting occult genitourinary cancer : Current Opinion in Urology Log in or Register Subscribe …

[HTML][HTML] Treatment outcomes for men with clinical stage II nonseminomatous germ cell tumours treated with primary retroperitoneal lymph node dissection: a …

A Neuenschwander, C Lonati, L Antonelli… - European Urology …, 2023 - Elsevier
Context Guidelines recommend primary retroperitoneal lymph node dissection (RPLND) as
a treatment option for tumour marker–negative stage II nonseminomatous germ cell tumour …